[Inefficacy of aflibercept in the treatment of idiopathic macular telangiectasia type 2  without neovascularization].

[Inefficacy of aflibercept in the treatment of idiopathic macular telangiectasia type 2 without neovascularization].
J Fr Ophtalmol. 2017 Aug 10;:
Authors: Bénichou J, Soler V, Denis D, Matonti F
Abstract
Idiopathic macular telangectasia type 2 is a rare disease consisting primarily of bilateral macular capillary telangiectasia, alterations of the ellipsoid zone and intraretinal cysts that may appear as cystoid macular edema in the absence of neovascularization. Our goal was to study the efficacy of aflibercept in the treatment of these cysts. Thus, we performed a series of three intravitreal injections of aflibercept in the right eye of a woman with a typical presentation of macular telangectasia type 2 complicated by cystoid macular edema without neovascularization. These injections did not significantly improve the anatomical or functional results. Other studies investigating the efficacy of other anti-VEGF in this disease led mainly to a decrease in macular thickness on OCT after injection, without any functional improvement. The anti-VEGFs therefore appear to be of little value in treating MacTel 2 intraretinal cysts without neovascularization.
PMID: 28803666 [PubMed - as supplied by publisher]

Source: Journal Francais d Ophtalmologie - August 15, 2017 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research